SCHEDULE: Baslake Partners Discloses 5% Stake in Athira Pharma

Baslake Partners, along with Baselake Management and David Paolella, has reported a 5.0% passive ownership stake in Athira Pharma, Inc.

Summary

• Baslake Partners, LP, Baselake Management, LLC, and David Paolella (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing indicates beneficial ownership of 197,481 shares of Athira Pharma, Inc. Common Stock.
• This represents 5.0% of the total outstanding shares of Athira Pharma, Inc.
• The shares are held by Baselake Partners, LP, with Baselake Management, LLC serving as the investment manager and David Paolella as its managing member.
• The Reporting Persons disclaim beneficial ownership except to the extent of their pecuniary interest.
• The percentage is calculated based on 3,943,887 shares outstanding as of November 5, 2025, as stated in the Issuer's 10-Q.

Sentiment

Score: 6

Explanation: The filing indicates a new institutional investor has taken a significant passive stake, which is generally a positive signal of confidence in the company's value, though it provides no operational or financial updates.

Positives

• Increased institutional ownership by Baselake Partners, potentially signaling confidence in Athira Pharma's long-term prospects.
• The filing is a passive investment, indicating no immediate intent to influence control, which can be viewed as a stable investment.

Negatives

• No specific negative information is contained within this beneficial ownership disclosure.

Risks

• No specific risks related to Athira Pharma, Inc. are disclosed in this Schedule 13G filing, as it is solely an ownership report.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Athira Pharma, Inc.'s future performance or strategic direction.

Industry Context

The disclosure of a new 5% passive stake by an investment firm like Baselake Partners in a biotechnology company such as Athira Pharma is a common occurrence in the industry. It reflects ongoing institutional interest in companies developing novel therapeutics, often driven by potential clinical trial outcomes or market opportunities for their drug candidates.

Stakeholder Impact

• Shareholders: May view the new institutional ownership as a positive indicator of market confidence, potentially leading to increased trading interest.
• Company Management: Awareness of a new significant shareholder, though the passive nature of the stake suggests no immediate pressure for strategic changes.

Key Dates

Keywords

Athira Pharma, Baslake Partners, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Biotechnology, Passive Stake